Tadalafil 5 mg once daily is a rationale option for simultaneous treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia and erectile 146 dysfunction
- Autores: Kaputovskij A.A1
-
Afiliações:
- A.I. Burnazyan SSCFMBC of FMBA of Russia
- Edição: Nº 6 (2019)
- Páginas: 146-149
- Seção: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/312390
- DOI: https://doi.org/10.18565/urology.2019.6.146-149
- ID: 312390
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
The lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) and erectile dysfunction (ED) are an important medical and social problem. Combination of LUTS and ED is usually underdiagnosed. Selective phosphodiesterase 5 inhibitors (PDE5I) are recommended for treatment of both conditions. The aim of this review is to identify the best PDE5I for simultaneous treatment LUTS and ED.
Texto integral
Sobre autores
A. Kaputovskij
A.I. Burnazyan SSCFMBC of FMBA of Russia
Email: kaputovsky79@mail.ru
aspirant of the Department of Urology and Andrology, IPPE Moscow, Russia
Bibliografia
- WHO. Ageing and health. http://www.who.int/mediacentre/factsheets/ fs404/en/
- Kok E.T., Schouten B.W., Bohnen A.M., Groeneveld F.P., Thomas S., Bosch J.L. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: The Krimpen study. J Urol. 2009;181:710-716.
- Jacobsen S.J., Jacobson D.J., Girman C.J.,Roberts R.O.,Rhodes T., Guess H.A., et al. Natural history of prostatism: Risk factors for acute urinary retention J Urol. 1997;158:481-487.
- Bosch J.L., Hop W.C., Kirkels W.J., SchruderF.H. Natural history of benign prostatic hyperplasia: Appropriate case definition and estimation of its prevalence in the community. Urology. 1995;46:34-40.
- Fong Y.K., Milani S., Djavan B. Natural history and clinical predictors of clinical progression in benign prostatic hyperplasia. CurrOpin Urol. 2005;15:35-38.
- Guess H.A., Arrighi H.M., Metter E.J., Fozard J.L. Cumulative prevalence of prostatism matches the autopsy prevalence of benign prostatic hyperplasia. Prostate. 1990;17:241-246.
- Chaitoff A., Killeen T.C., Nielsen C. Men’s health 2018: BPH, prostate cancer, erectile dysfunction, supplements. Cleve Clin J Med. 2018;85(11):871-880. doi: 10.3949/ccjm.85a.18011.
- Rosen R.C., Giuliano F., Carson C.C. Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Eur Urol. 2005;47(6):824-837.
- Roehrborn C.G., Nuckolls J.G. at al. The benign prostatic hyperplasia registry and patient survey: study design, methods and patient baseline characteristics.BJU Int. 2007;100(4):813-819.
- Shiri R., Hakkinen J.T. at al. Effect of lower urinary tract symptoms on the incidence of erectile dysfunction.J Urol. 2005l; 174(1): 205-209.
- Mondul A.M., Rimm E.B. et al. A prospective study of lower urinary tract symptoms and erectile dysfunction.J Urol. 2008; 179(6): 2321-2326.
- https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/#5
- Hatzimouratidis K. A review of the use of tadalafil in the treatment of benign prostatic hyperplasia in men with and without erectile dysfunction. Ther Adv Urol. 2014;6(4):135-147. doi: 10.1177/1756287214531639
- Kedia G., Uckert S. at all Effects of phosphodiesterase inhibitors on contraction induced by endothelin-1 of isolated human prostatic tissue. Urology 73: 1397-1401.
- Filippi, S., Morelli, A., at al. Characterization and functional role of androgen- dependent PDE5 activity in the bladder. Endocrinology. 2007;148:1019-1029.
- Yoshimura N., Seki S. De Groat W. Nitric oxide modulates Ca(2+) channels in dorsal root ganglion neurons innervating rat urinary bladder. J Neurophysiol. 2001;86:304-311.
- Morelli A., Sarchielli E. et al. Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. J Sex Med 2011;8:2746-2760.
- Bertolotto M., Trincia et al. Effect of tadalafil on prostate haemodynamics: preliminary evaluation with contrast-enhanced US. Radiol Med. 2009;114:1106-1114.
- Roumeguere T., Zouaou iBoudjeltia К. et al. Effects of phosphodiesterase inhibitors on the inflammatory response of endothelial cells stimulated by myeloperoxidase-modified low-density lipoprotein or tumor necrosis factor alpha. Eur Urol 2010;57: 522-528.
- Choi H., Kim H.J., Bae J.H., et al. A Meta-Analysis of Long- Versus ShortActing Phosphodiesterase 5 Inhibitors: Comparing Combination Use With a-Blockers and a-Blocker Monotherapy for Lower Urinary Tract Symptoms and Erectile Dysfunction. IntNeurourol J. 2015;19(4):237-245.
- Laydner H.K., Oliveira Р. et al. Phosphodiesterase 5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review. BJU International. 2011;107:1104-1109.
- Wang Y., Bao Y. et al. Tadalafil 5 mg Once Daily Improves Lower Urinary Tract Symptoms and Erectile Dysfunction: A Systematic Review and Meta-analysis. Lower Urinary Tract Symptoms. 2018;10:84-92.
- Oelke M., Giuliano F. at al. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomized, parallel, placebo-controlled clinical trial. Eur Urol. 2012;6(5):917-925.
Arquivos suplementares
